Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence

Ähnliche Einträge

• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  von: Christian Pfrepper, et al.
  Veröffentlicht: (2024)
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  von: Robert Klamroth, et al.
  Veröffentlicht: (2024)
• Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal
  von: Bishesh Sharma Poudyal, et al.
  Veröffentlicht: (2024)
• Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment
  von: Teruhisa Fujii, et al.
  Veröffentlicht: (2024)
• The impact of emicizumab on the clinical validation of new therapies for haemophilia A
  von: Cedric Hermans, et al.
  Veröffentlicht: (2024)